A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E

INTRODUCTION: High grade, non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical Bacillus Calmette-Gu ' erin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatment of NMIBC. OBJECTIVE: To evaluate the recurrence-free survival (RFS) of pati...

Descripción completa

Detalles Bibliográficos
Autores: Tan, WP, Bello, AP, Alvarez, CG, Guerrero-Ramos, F, Gonzalez-Padilla, DA, Nzeh, C, De la Morena, JM, De Torres, IGV, Hendricksen, K, Goizueta, FJD, Del Alamo, JF, Chiancone, F, Fedelini, P, Poggio, M, Porpiglia, F, Rodriguez, VCG, Torres, JM, Wilby, D, Robinson, R, Sousa-Escandon, A, Mata, JL, Moreno, JLP, Molina, FD, Semino, MAA, Stemberger, AT, Escudero, JC, Redorta, JP, Tan, WS
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p15528
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15528
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143830758&doi=10.3233%2fBLC-220026&partnerID=40&md5=22513bfc32e6b3f6815d00cb2b07be67
Access Level:acceso abierto
Palabra clave:Bladder hyperthermia
heated chemotherapy
heated mitomycin
intravesical chemotherapy
intravesical Mitomycin
HIVEC
Descripción
Sumario:INTRODUCTION: High grade, non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical Bacillus Calmette-Gu ' erin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatment of NMIBC. OBJECTIVE: To evaluate the recurrence-free survival (RFS) of patients treated with CHT using the Combat bladder recirculation system (BRS) for NMIBC. METHODS: This was a prospective multi-institutional study of 1,028 consecutive patients with NMIBC undergoing CHT between 2012 and 2020. A total of 835 patients were treated with CHT with Mitomycin C (MMC). Disease was confirmed on transurethral resection of bladder tumor (TURBT) prior to starting CHT. Follow-up included cystoscopy and subsequent TURBT if recurrence/progressionwas suspected. The primary endpointwas RFS. Secondary endpoints were progression-free survival (PFS) and adverse events from CHT. RESULTS AND LIMITATIONS: Median follow up was 22.4 months (Interquartile range (IQR): 12.8 - 35.8). Median age was 70.4 years (IQR: 62.1 - 78.6). A total of 557 (66.7%), 172 (20.6) and 74 (8.9%) of patients were classified to BCG naive, BCG unresponsive and BCG failure, respectively. The RFS at 12 months and 24 months for BCG naive was 87.6% (95% CI 85.0% - 90.4%) and 75.0% (95% CI 71.3% - 78.8%), respectively. The RFS at 12 months and 24 months for BCG unresponsive cohort was 78.1% (95% CI 72.0% - 84.7%) and 57.4% (95% CI 49.7% - 66.3%), respectively. The RFS at 24 months for the BCG unresponsive cohort for CIS with/without papillary disease and papillary only disease were 43.6% (95% CI 31.4% - 60.4%) and 64.5% (95% CI 55.4% - 75.1%), respectively. Minor adverse events occurred in 216 (25.6%) patients and severe events occurred in 17 (2.0%) patients. CONCLUSIONS: CHT with MMC using the Combat BRS is effective in the medium term and has a favorable adverse event profile.

Similares en LA Referencia